DDInter1763 DDInter1618
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924]. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide. Romosozumab is marketed in the United States by Amgen under the brand name Evinity. Romosozumab was granted FDA approval on April 9,2019.
Temsirolimus {u} (Compound) upregulates {v} (Gene) MKNK1
MKNK1 {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) upregulates {v} (Gene) MKNK1
MKNK1 {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) downregulates {v} (Gene) RCHY1
RCHY1 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is palliated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Temsirolimus (Compound) upregulates MKNK1 (Gene) and MKNK1 (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) upregulates MKNK1 (Gene) and MKNK1 (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) downregulates RCHY1 (Gene) and RCHY1 (Gene) is upregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is palliated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Temsirolimus (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is downregulated by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab